Genflow Biosciences Ltd (LSE:GENF, OTCQB:GENFF, FRA:WQ5) CEO Dr Eric Leire talked with Proactive's Stephen Gunnion about encouraging results from the SLAB (Sarcopenia and Longevity in Aged Beagles) trial, highlighting sustained efficacy and safety following treatment.
Leire explained that one of the most significant findings is the durability of the therapy’s effects. Even three months after stopping treatment, the benefits observed in the dogs have been maintained. He noted: "We stopped administration three months ago... and that's exactly what we see, both in terms of safety and in terms of efficacy." This persistence is a key milestone for gene therapy, as it could shift treatment from a repeated or chronic approach to a potential one-time intervention.
The durability of response also has broader implications for other indications Genflow is pursuing. Leire indicated that the results support expectations for similar long-lasting effects in future applications, including MASH.
While clinical endpoints are already showing promising outcomes, the company is awaiting additional data from blood analyses and biopsies to complement these findings. These results could further validate the therapy’s impact, including potential reductions in biological age. The existing data has already enabled early discussions with animal health companies regarding potential partnerships.
Watch the full interview to learn more about how Genflow is advancing gene therapy innovation.
For more videos like this, visit Proactive's YouTube channel, like this video, subscribe to the channel, and enable notifications so you never miss an update.
#GenflowBiosciences #GeneTherapy #SLABTrial #BiotechNews #LongevityScience #Sarcopenia #AnimalHealth #Biotechnology #ClinicalTrials #MASH #AgingResearch #HealthcareInnovation
